| Autor: |
Lobaina Y; CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.; CIGB: Vaccines & Pharmaceutics Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba., Chen R; CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.; Yongzhou Zhong Gu Biotechnology Co., Ltd, Yongzhou, China., Ai P; CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.; Yongzhou Zhong Gu Biotechnology Co., Ltd, Yongzhou, China., Yang L; Department of Laboratory Medicine, Dongguan Ninth People's Hospital, Dongguan, China., Alvarez-Lajonchere L; CIGB: Vaccines & Pharmaceutics Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba., Suzarte E; CIGB: Vaccines & Pharmaceutics Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba., Tan C; CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.; Yongzhou Zhong Gu Biotechnology Co., Ltd, Yongzhou, China., Silva R; CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.; BCF: BioCubafarma, Representative Office in China, Beijing, China., Jiang Z; Guangdong Eighth People's Hospital, Dongguan, China., Yang K; CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.; Yongzhou Zhong Gu Biotechnology Co., Ltd, Yongzhou, China., Perera Y; CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.; CIGB: Vaccines & Pharmaceutics Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba., Hermida L; CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.; BCF: BioCubafarma, Representative Office in China, Beijing, China. |
| Abstrakt: |
Since the beginning of the pandemic, the pre-existing immunity against SARS-CoV-2 has been postulated as one possible cause of asymptomatic infections. Later, various works reported that pre-existing immune response against the two structural conserved antigens: S2 subunit and the nucleocapsid protein, were associated to some level of asymptomatic profile in infected individuals. To explore the Ab background against these two antigens, in the context of vaccine-elicited and hybrid (natural infection plus vaccination induced) immunity of SARS-CoV-2, in this work, we tested sera from inactivated vaccine-immunized donors and from vaccinated and subsequent natural infected donors upon the Omicron variant wave in Guangdong province, China. Serum samples were collected from 27 COVID-19 convalescent, 25 SARS-CoV-2 vaccinated, and 10 negative donors. The IgG cross-reactivity response against these two antigens from another relevant human coronavirus (HCoV) was also evaluated. The findings indicate that IgG response against S2 and N protein was particularly higher in sera with hybrid immunity. The cross-reactive Abs were more significant against SARS-CoV-1, while a wide cross-reactivity was detected for N antigen for one human Alpha coronavirus HCoV-229E even in the negative control samples. The presence of cross-reactive Abs against the two conserved antigens N and S2, particularly in the context of hybrid immunity, could pave the way for future boosted vaccines carrying these conserved regions. |
